A drug used to treat insomnia has protected mice against the buildup of the ... There are almost 10 million new cases of dementia globally each year, and despite decades of research, there are still ...

Common sleep disorders include insomnia, sleep apnea and restless legs syndrome. From brain structure changes to increased risk of neurological disease, science is finding out just how important ...

Lemborexant, a medication commonly used to treat insomnia, may help protect the brain from tau buildup, a marker of Alzheimer's progression, a mouse study suggests.

The drug free treatment for insomnia Transcript ... A conservative estimate is that more than 40 per cent of Australians do not get a good night’s sleep.

Insomnia can happen for many reasons, does not have a lot of simple treatment options and is very common — all of us will suffer from insomnia at some point in our lives.

Diphenhydramine is the active ingredient in countless over-the-counter medications. But experts say there are serious risks to taking too much of the drug—or taking it too long.

Thousands of insomnia sufferers may be missing out on a groundbreaking treatment – simply because doctors don't know it exists, experts warn. Daridorexant was approved for use on the NHS in 2023 ...

This is the best type of exercise to fight insomnia if you’re over 60 By Diana Bruk Published March 17, 2025, 10:00 a.m. ET ...

Share on Pinterest Strength training could be the best weapon against insomnia in older adults, a recent study advises. Image credit: Guille Faingold/Stocksy. As much as 50% of older adults have ...

Past studies show that insomnia may increase a person’s risk for several health concerns, including heart disease, depression, cognitive impairment, dementia, and risk of falls.

The prevalence of RLS in the general population is between 4% to 29%. 3 The prevalence of RLS among older adults with dementia is likely higher than that of the general population due to the high ...

Separately, ZUNVEYL is also being developed in combination with memantine to treat moderate-to-severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.